Clinical trial
A Phase IIa Trial of Baricitinib in the Treatment of Kohlmeier-Degos Disease Patients With Neurological Involvement
NCT06923072 is registered in ClinicalTrials.gov with National Heart, Lung, and Blood Institute (NHLBI) as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase IIa Trial of Baricitinib in the Treatment of Kohlmeier-Degos Disease Patients With Neurological Involvement
- Lead sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
- Phase
- Phase 2
- Overall status
- Recruiting
- Start date
- February 18, 2026
- Completion date
- December 15, 2030
- Enrollment
- 12 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
degos disease, kohlmeier-degos disease, malignant atrophic papulosis, papulosis, malignant atrophic